

EXHIBIT GUIDE



Rheumatology Association of Iowa 11th Annual Meeting

February 28 - March 1, 2025
The Hotel at Kirkwood Center
Cedar Rapids, Iowa



AMGEN®

Table of CONTENTS

Industry Support 03

Program Schedule 04

**Rheumatology Association
of Iowa 11th Annual Meeting** 05

Exhibit Hall Floor Plan 06

THANK YOU TO OUR 2025 PROMOTIONAL SPONSORS

Platinum Level Sponsors



Inspired by patients.
Driven by science.

Gold Level Sponsors

abbvie



Johnson
& Johnson

KYOWA KIRIN

Silver Level Sponsors



sanofi

Thank You to Our 2025 Exhibitors

AbbVie
Alexion AstraZeneca Rare Disease
AMGEN, Inc.
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. - Medical Affairs
Genentech
GlaxoSmithKline
Johnson & Johnson
Kyowa Kirin, Inc.
Novartis
Pfizer, Inc.
Premier Specialty Network
Radius Health
Sanofi
Sobi, Inc.
UCB, Inc.

Program Schedule

Industry Sponsored Symposia

Saturday, March 1

9:00 a.m. – 10:00 a.m.

Industry Breakfast Symposium Sponsored by Amgen, Inc.

Location: Tippie Business Event Room

Achieving and Sustaining Remission in Severe Active ANCA-Associated

Vasculitis: GPA and MPA

Adam Kilian, MD

12:45 p.m. – 1:45 p.m.


Industry Lunch Symposium Sponsored by UCB, Inc.

Location: Tippie Business Event Room

BIMZELX Has Arrived in Rheumatology Expert Perspectives On A New

Treatment For PsA, nr-axSpA, And AS

Kurt Oelke, MD



**CURRENT GUIDELINES ESTABLISH GCs
AS THE STANDARD OF CARE FOR PMR.
HOWEVER, CHALLENGES REMAIN¹⁻⁴**

Explore treatment considerations in PMR,
by visiting the SANOFI booth

**Scan the QR code or visit PMRandIL6.com to
learn more about the pathogenesis of PMR.**



GCs=glucocorticoids; PMR=polymyalgia rheumatica.

References: 1. Buttgerit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. *JAMA*. 2016;315(22):2442-2458. 2. Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. *Clinical Rheum*. 2022;41:19-31. 3. Acharya S, Musa R. Polymyalgia Rheumatica. *NCBI Bookshelf*. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. 4. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. *Journal Rheumatol*. 2012;39(3):552-557.

sanofi | REGENERON

© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-US-2209515-v1.0 01/2023

Rheumatology Association of Iowa 11th Annual Meeting

All activities will be in the Ballroom unless noted otherwise.

FRIDAY, FEBRUARY 28, 2025

OVERVIEW

4:00 p.m. - 7:15 p.m. **Registration/Information Desk**
Location: Ballroom Corridor

6:00 p.m. - 7:15 p.m. **Exhibit Hall Open**
Location: Ballroom B & C

GENERAL SESSION

5:10 p.m. - 5:15 p.m. **Welcome & Opening**
Remarks

5:15 p.m. - 6:15 p.m. **CART Therapy in Rheumatic Disease**
Speaker: Alfred H. Kim, MD, PhD
Washington University School of Medicine

6:15 p.m. - 7:15 p.m. **Welcome Reception**
Location: Exhibit Hall

SATURDAY, MARCH 1, 2025

OVERVIEW

7:30 a.m. - 4:00 p.m. **Registration/Information Desk**
Location: Ballroom Corridor

8:30 a.m. - 2:30 p.m. **Exhibit Hall Open**
Location: Ballroom B & C

9:00 a.m. - 10:00 a.m. **Industry Symposium Breakfast**
Location: Tippie Business Event Room

12:45 p.m. - 1:45 p.m. **Industry Symposium Lunch**
Location: Tippie Business Event Room

GENERAL SESSION

8:10 a.m. - 8:15 a.m. **Welcome**

8:15 a.m. - 9:00 a.m. **Inflammatory Arthritis Secondary to Checkpoint Inhibitors**
Speaker: Jennifer Strouse, MD
University of Iowa

9:00 a.m. - 10:00 a.m. **Industry Symposium Breakfast**
Location: Tippie Business Event Room

10:00 a.m. - 10:45 a.m.

Preexisting Autoimmune Disease and Checkpoint Inhibitors
Speaker: Jennifer Strouse, MD
University of Iowa

10:45 a.m. - 11:15 a.m.

Break & Networking in Exhibit Hall

11:15 a.m. - 12:00 p.m.

Interesting Cases and Research Presentations
Moderator: Hanna Zembrzuska, MD, MME, FACP
University of Iowa

12:00 p.m. - 12:45 p.m.

Legal Aspects of Rheumatology Practice
Speakers: Tricia L. Hoffman-Simanek
Senior Vice President
Shuttleworth & Ingersoll P.L.C.
Mark P. Hudson
Senior Vice President
Shuttleworth & Ingersoll P.L.C.
Joseph M. Miller
Vice President
Shuttleworth & Ingersoll

12:45 p.m. - 1:45 p.m.

Industry Symposium Lunch
Location: Tippie Business Event Room

1:45 p.m. - 2:15 p.m.

Dessert & Networking in the Exhibit Hall

2:05 p.m. - 2:15 p.m.

RAI Annual Business Meeting

2:15 p.m. - 3:00 p.m.


CSRO Advocacy and Health Policy Update
Speaker: Michael S. Brooks, MD, FACP, FACR
CSRO

3:00 p.m. - 3:45 p.m.

Statehouse Insights
Speaker: Brett Barker, PharmD
Iowa House of Representatives

Final program, speaker bios, and CME information available online at virtual.association-service.org/rai

Exhibit Hall Floor Plan



| Company Name | Table # | Company Name | Table # |
|--|---------|---------------------------|---------|
| AbbVie | 1 | GlaxoSmithKline | 2 |
| Alexion AstraZeneca Rare Disease | 7 | Johnson & Johnson | 3 |
| AMGEN, Inc. - KRYSTEXXA | 13 | Kyowa Kirin, Inc. | 16 |
| AMGEN, Inc. - Evenity | 19 | Novartis | 12 |
| AMGEN, Inc. - Otezla and Enbrel | 20 | Pfizer, Inc. | 6 |
| AMGEN, Inc. - Taveos | 14 | Premier Specialty Network | 5 |
| AstraZeneca | 8 | Radius Health | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | Sanofi | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. - Medical Affairs | 11 | Sobi, Inc. | 18 |
| Genentech | 9 | UCB, Inc. | 15 |



Because nothing **else matters**

Our focus is on the moments that matter.
On seeking out scientific innovations with the greatest
impact on the lives of people with severe diseases.
On value that can't be expressed in numbers alone.

To learn more, visit
www.ucb-usa.com
© 2023 UCB, Inc. All rights reserved.



Inspired by **patients**.
Driven by **science**.

Patients say they're fine, but
**RA SAYS
OTHERWISE**

~ 1 in 3 patients with RA are not adequately controlled by bDMARD therapy after 1 year¹

Facilitating greater communication with your patients creates the opportunity to recognize uncontrolled RA.

Setting goals such as remission with your patients, and tracking them with tools such as RAPID3, leads to better outcomes. These goals are associated with reduced burden (e.g., reduction in fatigue, pain, and disability).²⁻⁴

Help Get Your Patient's RA Under Control at

REASSESSRA.COM




References: 1. Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry. *Rheumatol Ther*. 2017;4(2):489-502. doi:10.1007/s40744-017-0078-y 2. Ward MM, Castrejon I, Bergman MJ, Alba MI, Guthrie LC, Pincus T. Minimal clinically important improvement of Routine Assessment of Patient Index Data 3 in rheumatoid arthritis. *J Rheumatol*. 2019;46(1):27-30. doi:10.3899/jrheum.180153 3. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? *Arthritis Rheumatol*. 2014;66(4):775-782. doi:10.1002/art.38323 4. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. *Ther Adv Musculoskelet Dis*. 2017;9(10):249-262. doi:10.1177/1759720X17720366

bDMARD=biologic disease-modifying antirheumatic drug; RA=rheumatoid arthritis; RAPID3=Routine Assessment of Patient Index Data 3.

© 2023 AbbVie. All rights reserved. US-IMMR-230111 October 2023 Printed in U.S.A.

abbvie



Amgen is a proud sponsor of the RAI Annual Meeting

ABOUT AMGEN

Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today.

AMGEN



*Actor Portrayal

Inspired by patients, we take health personally

Breakthrough treatments that will shape the future of health care will only have impact if people can get them. We advocate for patients every step of the way, expanding access to our medicines and developing tools and programs so patients can receive optimal care.

Learn more at [jnj.com](https://www.jnj.com)

Johnson & Johnson

© Johnson & Johnson Health Care Systems Inc. 2024 04/24 cp-444097v1

Are you considering

X-linked hypophosphatemia?

XLH

is a progressive, lifelong, phosphorus-wasting disease. It is characterized by chronic hypophosphatemia due to increased FGF23 activity.¹



Progressive



Lifelong



↓ Phosphorus wasting



What do you need to know?



XLH is commonly misdiagnosed, which may lead to potentially inappropriate disease management.²



Learn how to accurately diagnose XLH



The signs and symptoms can vary in presentation and severity.^{2,3}



Contact a Kyowa Kirin rep to find out more and access additional XLH resources

Arlene and her daughter Gina
Living with XLH

FGF23=fibroblast growth factor 23; XLH=X-linked hypophosphatemia.

References: 1. Hamilton AA, Faltos S, Jones G, Kinsley A, Gupta RN, Lewiecki EM. Whole body, whole life, whole family: patients' perspectives on X-linked hypophosphatemia. *J Endocr Soc.* 2022;6(8):bvac086. doi:10.1210/endo/bvac086
2. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. *J Bone Miner Res.* 2011;26(7):1381-1388. doi:10.1002/jbmr.340 3. Trombetti A, Al-Daghri N, Brandi ML, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphatemia. *Nat Rev Endocrinol.* 2022;18(6):366-384. doi:10.1038/s41574-022-00662-x

Kyowa KIRIN

kyowakirin.com | XLHLinkHCP.com © 2024 Kyowa Kirin, Inc.
All rights reserved. COMM-US-RDS-0546 July 2024



XLHLinkHCP.com

Rheumatology Association of Iowa

P: (847) 517-7225 | F: (847) 517-7229

info@rheumiowa.org

